BiotechTube

aflibercept

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Exudative Age-related Macular Degeneration

Conditions

Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy

Trial Timeline

Sep 1, 2013 → Aug 1, 2015

NCT ID
NCT01950741

About aflibercept

aflibercept is a approved stage product being developed by Bayer for Exudative Age-related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT01950741. Target conditions include Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy.

What happened to similar drugs?

4 of 4 similar drugs in Exudative Age-related Macular Degeneration were approved

Approved (4) Terminated (0) Active (0)
✅ranibizumabNovartisApproved
✅ranibizumabNovartisApproved
✅AfliberceptRegeneron PharmaceuticalsApproved
✅Vascular endothelial growth factor trap-eyeBayerApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT04113538Phase 3UNKNOWN
NCT02633852ApprovedCompleted
NCT02661711Phase 2Completed
NCT02072408ApprovedCompleted
NCT02157077Phase 3Completed
NCT01950741ApprovedCompleted

Competing Products

5 competing products in Exudative Age-related Macular Degeneration

See all competitors
ProductCompanyStageHype Score
ranibizumabNovartisApproved
43
ranibizumabNovartisApproved
39
LHA510 ophthalmic suspension + LHA510 vehicle + Ranibizumab ophthalmic solutionNovartisPhase 2
35
AfliberceptRegeneron PharmaceuticalsApproved
43
Vascular endothelial growth factor trap-eyeBayerApproved
40